50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to build an oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0390% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2480% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0778% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2476% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2076% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2875% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2675% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2175% match
“Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2675% match
“Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1774% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1474% match
“Our mission is to develop a variety of first-in-class and best-in-class product candidates customized in an effort to optimize safety, efficacy, and convenience that we believe may offer improved patient experiences.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-03-1574% match
“Our mission is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2574% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0274% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0874% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2474% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1673% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0773% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2973% match
“Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3173% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3073% match
“Our mission is to build a world-class biopharmaceutical and biotechnology company, with a leading position in key therapeutic areas.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1273% match
“Our mission is to develop products and services based on leading genomics technologies that improve outcomes and enable improved effectiveness, productivity and safety in the research efforts of drug discovery and development companies worldwide.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1972% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2972% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0872% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0472% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0972% match
“Our mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2672% match
“Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-04-2972% match
“Our mission is to improve outcomes for patients living with cancer and genetically defined conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0272% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1372% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0572% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1872% match
“Our mission is to develop next-generation, potentially curative cell therapies for people with cancer.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1272% match
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0672% match
“Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2572% match
“Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-1272% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2872% match
“Our mission is to develop and market quality products backed by solid clinical research that will improve patient outcomes and meet the needs of our surgical customers with maximum effectiveness and safety.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-03-1672% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3171% match
“Our mission is to develop new medicines to treat and cure patients with solid tumors using our next generation TIL therapy approach.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2271% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1971% match
“Our mission is to develop next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-11-2871% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2871% match
“Our mission is to be the leading player in the development and commercialization of p53-targeted cancer therapies.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1571% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1671% match
“Our mission is to become a leading fully-integrated pharmaceutical company delivering new medicines to patients with unmet medical needs.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-2871% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2171% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0571% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0171% match
Showing 1–50 of 50